These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12007589)

  • 1. Changes in central serotonergic function as a correlate of duration of illness in paranoid schizophrenia.
    Angelopoulos EK; Markianos M; Daskalopoulou EG; Hatzimanolis J; Tzemos J
    Psychiatry Res; 2002 May; 110(1):9-17. PubMed ID: 12007589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
    Markianos M; Hatzimanolis J; Lykouras L
    Psychopharmacology (Berl); 2001 Aug; 157(1):55-9. PubMed ID: 11512043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin in childhood obsessive-compulsive disorder: clinical correlates and response to clomipramine.
    Hanna GL; McCracken JT; Cantwell DP
    J Am Acad Child Adolesc Psychiatry; 1991 Mar; 30(2):173-8. PubMed ID: 2016218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects.
    Copolov DL; Keks NA; Kulkarni J; Singh BS; McKenzie D; McGorry P; Hill C
    Psychoneuroendocrinology; 1990; 15(3):225-31. PubMed ID: 2255750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonergic and dopaminergic neuroendocrine responses of male depressive patients before and after a therapeutic ECT course.
    Markianos M; Hatzimanolis J; Lykouras L
    Eur Arch Psychiatry Clin Neurosci; 2002 Aug; 252(4):172-6. PubMed ID: 12242578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia.
    Krystal JH; Seibyl JP; Price LH; Woods SW; Heninger GR; Aghajanian GK; Charney DS
    Arch Gen Psychiatry; 1993 Aug; 50(8):624-35. PubMed ID: 8102048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haloperidol plasma levels and clinical response in paranoid schizophrenics.
    Linkowski P; Hubain P; von Frenckell R; Mendlewicz J
    Eur Arch Psychiatry Neurol Sci; 1984; 234(4):231-6. PubMed ID: 6526061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between prolactin responses to ECT and dopaminergic and serotonergic responsivity in depressed patients.
    Markianos M; Hatzimanolis J; Lykouras L
    Eur Arch Psychiatry Clin Neurosci; 2002 Aug; 252(4):166-71. PubMed ID: 12242577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems.
    Keks NA; Copolov DL; Kulkarni J; Mackie B; Singh BS; McGorry P; Rubin RT; Hassett A; McLaughlin M; van Riel R
    Biol Psychiatry; 1990 Jun; 27(11):1203-15. PubMed ID: 2354227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
    Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
    Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients.
    Abel KM; O'Keane V; Murray RM
    Br J Psychiatry; 1996 Jan; 168(1):57-60. PubMed ID: 8770429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine receptor responsivity in schizophrenic patients before and after switch from haloperidol to risperidone.
    Markianos M; Hatzimanolis J; Lykouras L
    Psychiatry Res; 1999 Dec; 89(2):115-22. PubMed ID: 10646830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperdopaminergia in schizophreniform psychosis: a chronobiological study.
    Rao ML; Gross G; Halaris A; Huber G; Marler M; Strebel B; Bräunig P
    Psychiatry Res; 1993 May; 47(2):187-203. PubMed ID: 8341771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of haloperidol on somatostatin-like immunoreactivity in the CSF of Schizophrenic patients.
    Gattaz WF; Rissler K; Gattaz D; Cramer H
    Psychiatry Res; 1986 Jan; 17(1):1-6. PubMed ID: 2868477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of psychotic symptoms to haloperidol-stimulated prolactin release.
    Kulkarni J; Keks NA; Stuart G; Mackie B; Minas IH; Singh BS; Copolov DL
    Acta Psychiatr Scand; 1990 Oct; 82(4):271-4. PubMed ID: 2260479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.